NantHealth Inc (NYSE:NH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
NH has been the subject of several other reports. Canaccord Genuity reissued a “buy” rating and issued a $17.00 target price on shares of NantHealth in a research note on Monday, September 19th. FBR & Co reissued a “buy” rating on shares of NantHealth in a research note on Wednesday, August 10th. Cowen and Company started coverage on shares of NantHealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 target price for the company. Jefferies Group started coverage on shares of NantHealth in a research note on Monday, June 27th. They issued a “buy” rating for the company. Finally, First Analysis started coverage on shares of NantHealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $18.00.
NantHealth (NYSE:NH) opened at 13.72 on Thursday. The firm’s market cap is $1.66 billion. The stock has a 50 day moving average of $12.79 and a 200-day moving average of $12.63. NantHealth has a 52 week low of $9.79 and a 52 week high of $16.63.
NantHealth (NYSE:NH) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.26. The business had revenue of $31.50 million for the quarter, compared to the consensus estimate of $23.55 million. The firm’s quarterly revenue was up 166.9% on a year-over-year basis. Analysts expect that NantHealth will post ($0.59) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in NantHealth during the second quarter worth approximately $11,250,000. Wildcat Capital Management LLC bought a new position in NantHealth during the second quarter worth approximately $3,008,000. Jefferies Group LLC bought a new position in NantHealth during the second quarter worth approximately $6,943,000. Finally, Blackstone Group L.P. bought a new position in NantHealth during the second quarter worth approximately $7,463,000.
NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.